Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + hydroxyurea + paclitaxel
- Development stage
- Unknown
- Lead developer
- GERCOR
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
fluorouracil + hydroxyurea + paclitaxel is a combination chemotherapy regimen investigated by the GERCOR (Multidisciplinary Oncology Cooperative Group) for the treatment of inoperable stage II or III epidermoid carcinoma of the esophagus. This regimen is administered concurrently with radiation therapy (chemoradiotherapy). It combines the microtubule-stabilizing effects of paclitaxel, the thymidylate synthase inhibition of fluorouracil (5-FU), and the ribonucleotide reductase inhibition of hydroxyurea. These agents act as radiosensitizers, aiming to improve the local control and survival rates of patients with esophageal cancer compared to radiation or dual-agent chemotherapy alone. The regimen was evaluated in a multicenter Phase I/II clinical trial to determine its efficacy and safety profile in this specific patient population.
- Other names
- paclitaxel-GERCOR5-FU + hydroxyurea + paclitaxelGERCOR esophageal cancer regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + hydroxyurea + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + hydroxyurea + paclitaxel.